drugset / Trial / NCT04832958

Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

NCT04832958 ↗

Phase 2 Completed 81 enrolled IRCCS San Raffaele
NaSingle-groupOpen-labelDiagnostic

Summary

The project aims at assessing the role of radio-guided surgery in the detection of lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) by using an intraoperative gamma probe and a radioactive labelled PSMA ligand (99mTc-PSMA-I\&S). We hypothesize that 99mTc-PSMA-I\&S radio-guided surgery (99mTc-PSMA-RGS) might assist physicians in the identification of patients with LNI candidate for an extended pelvic lymph node dissection (ePLND). Overall, 100 men with a LNI risk \>5% according to the Briganti nomogram will be submitted to 68Ga-PSMA PET/MRI followed by 99mTc-PSMA-RGS and ePLND. The aims are 1) to assess the safety and tolerability of 99mTc-PSMA-I\&S; 2) to assess the accuracy of 99mTc-PSMA-RGS in the identification of LNI compared to available clinical tools and to molecular imaging (i.e., 68Ga-PSMA PET/MRI); 3) to assess whether 99mTc-PSMA-RGS would allow for the identification of positive nodes outside the standard ePLND template.

Timeline

Start
2021-05-15
Primary completion
2024-11-15
Completion
2024-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 99mTc-PSMA-I&S Diagnostic / imaging agent — Intravenous

Indications